Safety and Efficacy of Different Formulations of Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

• Status: Completed
• Trial end date: 2011-04-29
• Target enrollment: 0
• Participant gender: All

Summary

This study will evaluate the safety and efficacy of bimatoprost 0.03% formulation B ophthalmic solution with LUMIGAN® (bimatoprost ophthalmic solution 0.03%) once daily for 12 weeks in patients with glaucoma or ocular hypertension

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Allergan
• Treatments: Bimatoprost; Ophthalmic Solutions; Pharmaceutical Solutions

Criteria

Inclusion Criteria:

• Patient has ocular hypertension or glaucoma in both eyes

• Requires IOP-lowering therapy in each eye

Exclusion Criteria:

• Active or recurrent eye disease that would interfere with interpretation of study data in either eye

• History of any eye surgery or laser in either eye within 6 months

• Required chronic use of other eye medications during the study

• Anticipated wearing of contact lenses during the study.

• Intermittent use of oral, intramuscular, or intravenous corticosteroids within 21 days